Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Drugs Controller General of India (DCGI) approved India's first Quadri-valent Human Papillomavirus vaccine (qHPV) against cervical cancer.